S1-221

Delphian Therapeutics Australia Pty, Ltd · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	S1-221
Sponsor	Delphian Therapeutics Australia Pty, Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study Testing the Safety and Effects of Single Doses of S1-221 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

S1-221 CI brief — competitive landscape report
S1-221 updates RSS · CI watch RSS
Delphian Therapeutics Australia Pty, Ltd portfolio CI